Second-Line Treatment of Ovarian Cancer

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 • 1,393 citations

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

1994 • 1,355 citations

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

1991 • 824 citations

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

1997 • 662 citations

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1997 • 648 citations

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

1994 • 639 citations

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1995 • 476 citations

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

1998 • 393 citations

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

1996 • 384 citations

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1990 • 384 citations

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1994 • 379 citations

Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients

1994 • 332 citations

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

1998 • 331 citations

Interaction between cisplatin and gemcitabine in vitro and in vivo.

1995 • 314 citations

Cancer of the Ovary

1993 • 288 citations

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1996 • 253 citations

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.

1997 • 246 citations

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin

1998 • 239 citations

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.

1996 • 213 citations

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second-line therapy in 105 patients

1991 • 209 citations

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.

1991 • 186 citations

Chemotherapy of advanced ovarian cancer.

1998 • 170 citations

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.

1994 • 167 citations

Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

1994 • 166 citations

Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report

1996 • 155 citations

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.

1996 • 138 citations

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.

1992 • 137 citations

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.

1998 • 129 citations

Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.

1989 • 128 citations

Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian Cancer

1995 • 125 citations

High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients.

1997 • 123 citations

Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.

1995 • 122 citations

Chemotherapy for advanced ovarian cancer

1999 • 109 citations

Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.

1993 • 107 citations

High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results.

1997 • 98 citations

Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.

1989 • 91 citations

Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy.

1989 • 87 citations

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

1992 • 74 citations

Intraperitoneal therapy of ovarian cancer.

1998 • 73 citations

Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial

1998 • 66 citations

European-Canadian randomized trial of Paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1998 • 66 citations

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.

1997 • 66 citations

Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer

1992 • 54 citations

Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

1998 • 43 citations

A Phase I Study of a Daily ×3 Schedule of Intravenous Vinorelbine for Refractory Epithelial Ovarian Cancer

1998 • 37 citations

The ?failure free interval? defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing

1991 • 36 citations

Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.

1998 • 34 citations

Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials

1995 • 33 citations

Follow-up of the Asymptomatic Patient with Ovarian Cancer

1994 • 32 citations

A Phase 2 Trial of Ifosfamide/Mesna as Salvage Therapy in Patients with Ovarian Cancer Refractory to or Relapsing after Prior Platinum-Containing Chemotherapy

1995 • 29 citations

Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer

2001 • 24 citations

Phase I Study of Paclitaxel, Carboplatin, and Increasing Days of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study

2000 • 21 citations

Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma

1998 • 18 citations

Phase I studies of gemcitabine combined with carboplatin or paclitaxel.

1997 • 18 citations

Tamoxifen in relapsed ovarian cancer: A systematic review

1998 • 16 citations

Cycles of Dose-Intensive Chemotherapy with Peripheral Stem Cell Support in Persistent or Recurrent Platinum-Sensitive Ovarian Cancer

1997 • 5 citations

Cited By (0)

Loading...